Kepivance
·
- Prescription status not stated
- Everything that fits nowhere else, such as contrast media
- Active substance
- Palifermin
- Made by
- Swedish Orphan Biovitrum AB (publ)
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Kepivance is indicated to decrease the incidence, duration and severity of oral mucositis in adult patients with haematological malignancies receiving myeloablative radiochemotherapy associated with a high incidence of severe mucositis and requiring autologous-haematopoietic-stem-cell support.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
Details
| Made by | Swedish Orphan Biovitrum AB (publ) |
|---|---|
| Active substance | Palifermin |
| Used in | Everything that fits nowhere else, such as contrast media |
| Classification | V03AF08 · Everything that fits nowhere else, such as contrast media |
| Authorised on | 2005-10-25 |
| Last updated by the regulator | 2016-04-08 |
| EMA product number | EMEA/H/C/000609 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).